Drug Sponsors

Zilliqa and Global Brain Blockchain Labs partner

Monday, December 11, 2017

Zilliqa, a highly anticipated blockchain platform based on the technology of sharding, has announced a partnership with GB Blockchain Labs (GBBL), the blockchain arm of Global Brain, one of the largest VC firms in Japan. Zilliqa will also be part of the Global Brain Alliance Forum 2017 to be held in Tokyo on December 8.

[Read More]

Melinta Therapeutics to acquire Infectious Disease Business from The Medicines Company

Monday, December 4, 2017

Melinta Therapeutics, a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial infections, announced that Melinta and The Medicines Company have entered into an agreement pursuant to which Melinta will acquire the infectious disease business from The Medicines Company. This includes three marketed products: recently approved and launched Vabomere (vaborbactam/meropenem), and established commercial products Orbactiv (oritavancin) and Minocin IV (minocycline). 

[Read More]

AstraZeneca, FIIF establish joint venture to develop new medicines in China

Friday, December 1, 2017

AstraZeneca announced a strategic joint venture with the Chinese Future Industry Investment Fund (FIIF) to form an equally-owned, stand-alone company in China to discover, develop and commercialize potential new medicines to help meet unmet needs globally, and to bring innovative new medicines to patients in China faster. FIIF is managed by the SDIC Fund Management Company (SDIC Fund), a private equity management company.

[Read More]

Teva restructures

Monday, November 27, 2017

Teva Pharmaceutical Industries announced a new organization and leadership structure aimed to achieve better commercial focus and drive value creation. The new structure will enable strategic alignment across the portfolio, across regions and between functions, leveraging scale, enhancing agility, extracting efficiencies and providing increased proximity to the markets. This new structure will be implemented effective immediately.

[Read More]

Purdue Pharma invests in oncology R&D

Wednesday, November 15, 2017

Purdue Pharma announced completion of significant oncology related investments as part of its ongoing efforts to diversify its scientific research into areas of high unmet medical need. Through these investments, executed over a multi-year period and capped recently in 2017, Purdue is establishing a portfolio of drug candidates with the potential to deliver new cancer therapies to patients within the next five years.

[Read More]

Sangamo plans new headquarters in Brisbane, California

Friday, November 10, 2017

Sangamo Therapeutics announced plans for new corporate headquarters at 7000 Marina Boulevard, an 88,000 square foot building at Oyster Point in Brisbane, California, in the heart of the biotech hub south of San Francisco. Occupancy of the Brisbane site is expected in late 2018, after completion of architectural improvements. The Company will retain its Point Richmond location as a Sangamo Research Center.

[Read More]

Mallinckrodt to acquire Ocera Therapeutics

Thursday, November 2, 2017

Mallinckrodt, a global specialty pharmaceutical company, and Ocera Therapeutics have entered into an agreement under which Mallinckrodt will acquire Ocera, a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for orphan and other serious liver diseases with high unmet medical need. Ocera’s developmental product OCR-002, an ammonia scavenger, is being studied for treatment of hepatic encephalopathy, a neuropsychiatric syndrome associated with hyperammonemia, a complication of acute or chronic liver disease.

[Read More]